KKR To Invest In Arbor Pharmaceuticals

ATLANTA & NEW YORK--(BUSINESS WIRE)--Arbor Pharmaceuticals (“Arbor”), a specialty pharmaceutical company, today announced that KKR, a leading global investment firm, is acquiring a significant minority stake in the company. Financial terms of the transaction were not disclosed. Acquired by its current investor group in 2010, Arbor markets branded prescription products for the cardiovascular, hospital, and pediatric markets as well as generic products through its Wilshire division. The company has completed over twenty acquisition, licensing, or product development transactions over the past four years and has multiple products filed with the FDA as well as several branded and generic products in late-stage development.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC